life scienc diagnost tool
brammer tuck-in strengthen
capabl reiter buy rais pt
minim revenue/ep impact nt gain valuabl capabl
support one fastest grow area within biopharma end
market rais pt larg reflect sector-wid
multipl expans march announc definit plan
acquir privately-held brammer cash brammer
contract develop manufactur organ
lead expertis viral vector develop manufactur gene
cell therapi estim gene cell therapi
manufactur market outsourc grow
annual brammer expect gener revenu
accret ep first year grow faster
overal market acquisit expect close end
make lot strateg sens view particularli given tmo
success foray market patheon acquisit
strong competit posit within fastest grow segment
biopharma custom base potenti synergi tmo
product today serv gene cell therapi custom
instrument relat consum repres
brammer robust growth potenti highli attract gene cell
therapi market potenti gene cell therapi ind file
fda current fda anticip gene cell therapi
ind per year product approv year
current shortag viral vector manufactur capac expertis
comparison preced transactions/compar compani trade
multipl ltm sale patheon acquisit base msd hsd
growth potenti ntm sale rate
maintain estim close deal
valuat pt base price-to-earnings in-lin
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
brammer provid clinic commerci suppli viral vector vivo
gene therapi ex vivo gene-modifi cell therapi well process
analyt develop regulatori support servic biopharma
brammer employe doubl last year
facil locat alachua florida feet clinic suppli plan
expand process analyt develop lab qc lab wareh
earli cambridge/lexington/somervil massachusett first
foot commerci facil cambridg plan expand
suspens large-scal adher process second
commerci facil lexington current renov
foot facil adher process complet
squar foot distribut center somervil
brammer found merger florida biologix spin-out
univers florida brammerbio pharmaceut brammer
acquir cambridg somervil facil neutral
analyst thoma shrader januari brammer own ampersand
capit partner founder
thoma shrader enter manufactur collabor brammer
fujifilm diosynth technolog privat particularli relat
system manufactur adeno-associ viru aav gene
therapi vygr manufactur strategi build intern preclin
clinic process analyt develop scale-up expertis partner
cdmo larger-scal redund suppli commercial-stag
manufactur collabor entail brammer implement
commercially-readi manufactur process cgmp cambridg
facil fujifilm first-in-human cgmp clinic trial materi product
capac colleg station tx facil
chiang enter long-term strateg partnership brammer
brammer provid sarepta clinic commerci manufactur capac
sarepta micro-dystrophin duchenn muscular dystrophi gene therapi
program potenti futur program limb girdl muscular
dystrophi srpt strategi continu build intern expertis aav-
base manufactur leverag brammer scalabl manufactur
recent capac expans cell gene therapi
exhibit select recent cell gene therapi manufactur capac
btig cover compani mention report
appendix analyst certif import disclosur
